BioXcel Therapeutics, Inc.: Clinical stage company utilizing AI technology platform to identify improved therapies in neuroscience and immuno-oncology. BXCL501 (sublingual dexmedetomidine): Phase 3 trials ongoing for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). Topline data expected mid-2020; Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. Data expected mid-2020; BXCL701 (innate immunity activator): Phase 1b/2 ongoing of BXCL701 and KEYTRUDA for Prostate Cancer (tNEPC).
Based in...
US - New England
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Oncology
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Platform Technology, Small Molecule
555 Long Wharf Drive
5th Floor
New Haven, Connecticut 06511
United States

Top 10 Holders of BioXcel Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
State Street Corp. 5.40 974,381 47.16 13F 6/30/20
DNCA Finance SA 3.99 892,453 43.19 Stakes 3/3/20
The Vanguard Group, Inc. 4.05 730,838 35.37 Funds 8/31/20
Artemis Investment Management LLP 3.89 701,498 33.95 13F 6/30/20
Vanguard Group, Inc. (Subfiler) 3.01 543,381 26.30 13F 6/30/20
AllianceBernstein LP 2.80 504,405 24.41 13F 6/30/20
Avidity Partners Management LP 2.15 388,095 18.78 13F 6/30/20
BlackRock Fund Advisors 2.02 364,425 17.64 13F 6/30/20
Acuta Capital Partners LLC 1.89 340,500 16.48 13F 6/30/20
Citadel LP 1.74 313,962 15.20 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.